Intellicheck 3Q 2026: Revenue $5.74M, EPS $0.02 — 10-Q Summary

Intellicheck reported 3Q 2026 revenue of $5.74M, down 5% YoY, and net income of $471K, up 62.4% YoY. EPS was $0.02. Revenue decline was due to lower transaction volumes and non-recurring engineering revenue, partially offset by a 7% decrease in operating expenses. A major customer reduced volumes by 35% YoY, impacting revenue.

Original reporting
Published Nov 12, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Intellicheck 3Q 2026: Revenue $5.74M, EPS $0.02 — 10-Q Summary — source image
Decision brief

The 30-second read

$IDNBearishMed
01

Why it matters

The fresh earnings numbers provide a basis for short‑term trading decisions, especially for momentum‑focused traders.

02

Market read

Micro‑cap earnings release with mixed results; likely short‑term price volatility.

03

What to watch

Operating expense cuts and lower R&D spending may improve margins over the next quarters.

Relevance 6/10Novelty 7/10Timing: after-hours filing

Background

Intellicheck Inc. (NASDAQ: IDN) filed its Q3 2026 Form 10‑Q, showing a modest revenue decline and improved profitability.

Company-level read

Ticker impact

$IDNBearishHigh confidence
Context

Intellicheck reported Q3 2026 revenue of $5.74M, a 5% decline YoY, and EPS of $0.02 in its 10‑Q filing.

Expected impact

likely downside as investors price in the revenue decline

Evidence & confidence

The 5% revenue drop and reduced customer volumes are fresh data not previously disclosed, which typically triggers a sell pressure in micro‑caps.

Market effects

The decline may signal softness in the identity‑verification SaaS niche.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global impact given the company's size.

Counterpoint

Net income rose 62% YoY, which could attract value buyers despite revenue dip.

Key entities

  • Intellicheck Inc.

    Provider of identity verification and fraud prevention solutions.

Related articles

$IDNMed

Intellicheck Reports Third Quarter 2026 Results

Intellicheck, Inc. (IDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Intellicheck Reports Third Quarter 2026 Results Net Income Rises to $0.5 Million Adjusted EBITDA Increases to $0.9 Million Cash Balance Grows to $13.2 Million, Highest Level Since the End of 2021, with No Debt MELVILLE, NEW YORK – November 12, 2026 – Intellicheck, Inc. (Nasdaq: I

$IDNMed

Intellicheck Reports Second Quarter 2026 Results

Intellicheck, Inc. (IDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Intellicheck Reports Second Quarter 2026 Results Revenue Grows 16% to $5.9 Million Net Income Rises to $0.7 Million Adjusted EBITDA Increases to $1.1 Million MELVILLE, NEW YORK – August 13, 2026 – Intellicheck, Inc. (Nasdaq: IDN) (“Intellicheck” or the “Company”), an industry-lea

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.